525 | 0 | 38 |
下载次数 | 被引频次 | 阅读次数 |
总结韩明向教授治疗慢性阻塞性肺疾病(COPD)的临证经验。认为外邪侵袭引动宿疾是COPD急性加重期的关键病机,肺气虚是稳定期的关键病机,“虚、痰、瘀”为疾病发展过程中的核心病理要素。治疗上强调分期分证论治,急性加重期中,针对风寒袭肺证,自拟三子温肺汤以解表散寒、温肺化痰;针对痰湿蕴肺证,自拟化痰降气方以温肺化痰、降气平喘;针对痰热壅肺证,自拟清肺化痰方以清热化痰、润肺止咳;针对痰瘀互结证,自拟芪白平肺方以益气化痰、活血化瘀。稳定期中,针对肺气虚证,自拟参芪温肺汤以温肺益气、化痰泻浊;针对肺脾气虚证,自拟参芪补中汤以健脾益气、培土生金;针对肺肾亏虚证,自拟参芪调肾方以补肺温阳、纳肾平喘,为COPD中医治疗提供思路。
Abstract:This paper summarizes Professor HAN Mingxiang's clinical experience in treating chronic obstructive pulmonary disease(COPD). He believes that the key pathomechanism of COPD in the acute exacerbation stage is the invasion of external pathogens triggering latent illness, while lung qi deficiency is the primary mechanism in the stable stage. The core pathological factors throughout disease progression are deficiency, phlegm, and blood stasis. Treatment emphasizes a staged and syndrome-based approach. During the acute exacerbation stage, for wind-cold invading the lung syndrome, the self-formulated Sanzi Wenfei Decoction (三子温肺汤) is used to relieve the exterior, dispel cold, warm the lung, and resolve phlegm. For phlegm-dampness obstructing the lung syndrome, Huatan Jiangqi Fomulation (化痰降气方) is prescribed to warm the lung, transform phlegm, descend qi, and calm wheezing. For phlegm-heat obstructing the lung syndrome, Qingfei Huatan Fomulation (清肺化痰方) is applied to clear heat, resolve phlegm, moisten the lung, and stop coughing. For phlegm and blood stasis interlocking syndrome, Qibai Pingfei Fomulation (芪白平肺方) is used to tonify qi, resolve phlegm, and activate blood circulation to remove stasis.During the stable stage, for lung qi deficiency syndrome, Shenqi Wenfei Decoction (参芪温肺汤) is employed to warm the lung, tonify qi, resolve phlegm, and eliminate turbidity. For lung-spleen qi deficiency syndrome, Shenqi Buzhong Decoction (参芪补中汤) is utilized to strengthen the spleen, tonify qi, and reinforce metal(lung) from earth(spleen). For lung-kidney deficiency syndrome, Shenqi Tiaoshen Fomulation (参芪调肾方) is prescribed to tonify the lung, warm yang, and regulate kidney function to calm wheezing. These strategies provide insights into the traditional Chinese medicine treatment of COPD.
[1]PATEL N.An update on COPD prevention,diagnosis,and management:the 2024 GOLD report[J].Nurse Pract,2024,49(6):29-36.
[2]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.
[3]AGUSTI A,CELLI BR,CRINER GJ,et al.Global initiative for chronic obstructive lung disease 2023 report:GOLD executive summary[J].Eur Respir J,2023,61(4):2300239.
[4]TSE G,EMMANUEL B,ARITI C,et al.A long-term study of adverse outcomes associated with oral corticosteroid use in COPD[J].Int J Chron Obstruct Pulmon Dis,2023,18:2565-2580.doi:10.2147/COPD.S433326.
[5]SKOLNIK NS,NGUYEN TS,SHRESTHA A,et al.Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators[J].Postgrad Med,2020,132(2):198-205.
[6]吴蕾,郑俐慈,陈远彬,等.基于宗气、元气理论探讨慢性阻塞性肺疾病的病机与辨治[J].中医杂志,2023,64 (14):1440-1443.
[7]黄丽娜,高峰.从“使邪有出路”论利水渗湿药在慢性阻塞性肺疾病治疗中的应用[J].中医杂志,2021,62(13):1179-1181.
[8]张冬,徐娇,石惟嫦,等.哮喘-慢性阻塞性肺病重叠的发病机制及中西医诊治研究进展[J].成都医学院学报,2023,18(6):799-803.
[9]XIONG C,LI Y,ZHUANG G,et al.Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease:a systematic review and meta-analysis[J].Complement Ther Med,2021,59:102691.doi:10.1016/j.ctim.2021.102691.
[10]方伟.基于UPLC-Q/TOF-MS法的化痰降气方化学成分分析及慢性阻塞性肺疾病代谢组学初步研究[D].合肥:安徽中医药大学,2019.
[11]王梦文,郭艳,王重阳,等.化痰降气胶囊含药血清调控Nrf2/HDAC2改善16HBE细胞糖皮质激素抵抗[J].中国临床药理学与治疗学,2021,26(12):1360-1369.
[12]朱张求,朱洁,童佳兵,等.基于JAK1/STAT3信号通路研究芪白平肺胶囊对COPD继发PAH大鼠的影响[J].中华中医药杂志,2023,38(1):324-330.
[13]石孟瑶,朱洁,方莉,等.芪白平肺胶囊对COPD痰瘀阻肺证大鼠肺血管Bax、Bcl-2表达的影响[J].中医药学报,2022,50(4):23-27.
[14]李泽庚,王传博,彭波,等.芪白平肺胶囊对慢性阻塞性肺疾病患者BODE指数的影响[J].中医杂志,2010,51 (11):987-989.
[15]韩明向,李泽庚.肺气虚证浅探[J].安徽中医学院学报,1993,12(2):2-4.
[16]马啸,童佳兵,杨程,等.基于新安医学固本培元思想研究肺胀[J].中医杂志,2014,55 (4):299-300.
[17]慈慧敏,许浩燃,丁焕章,等.基于Th17/Treg失衡探讨参芪温肺汤治疗COPD肺气虚证的作用机制[J].时珍国医国药,2024,35(1):65-67.
[18]吴迪,王小乐,高雅婷,等.参芪温肺方减轻慢性阻塞性肺疾病大鼠的肺气虚证:基于调节NLRP3/GSDMD细胞焦亡通路[J].南方医科大学学报,2023,43(9):1500-1508.
[19]杨勤军,王卉,徐淑钰,等.参芪调肾方减轻慢阻肺肺肾气虚证大鼠气道炎症的机制:基于铁死亡途径[J].南方医科大学学报,2024,44(10):1937-1946.
[20]周凡超,杨勤军,吴迪,等.参芪调肾方通过OPG/RANKL/NF-κB/MMP-9通路抑制慢阻肺炎症介导的骨吸收[J].中药药理与临床,2024,40(4):54-60.
基本信息:
DOI:10.13288/j.11-2166/r.2025.08.004
中图分类号:R249;R259
引用信息:
[1]丁健,陶慧,程刚等.韩明向分期分证治疗慢性阻塞性肺疾病经验[J].中医杂志,2025,66(08):780-785.DOI:10.13288/j.11-2166/r.2025.08.004.
基金信息:
国家自然科学基金(82374399); 国家自然科学基金区域创新发展联合基金重点支持项目(U20A20398); 安徽省科学技术厅临床医学研究转化专项(202204295107020045)